Myriad to Acquire Assurex

Myriad Genetics has announced that it has signed a definitive agreement to acquire Assurex Health, a global leader in genetic testing for psychotropic medicine selection, for $225 million upfront with the potential for $185 million in additional performance-based milestones. Assurex generated revenue of more than $60 million and tested more than 150,000 patients in Myriad's fiscal year 2016.

The transaction is expected to close at the end of Myriad's first quarter of fiscal year 2017. Myriad will provide financial guidance pertaining to the acquisition when the Company hosts its fourth-quarter earnings call on August 9, 2016.  A discussion on the details and strategy underlying this acquisition will be provided on a conference call today at 4:30 pm EDT.

"Assurex provides Myriad access to GeneSight® one of the fastest growing new diagnostic tests ever in a multi-billion dollar global market and builds upon Myriad's commitment to expand into neuroscience, positioning us for long-term growth," said Mark C. Capone, president and CEO, Myriad Genetics. "Importantly, this acquisition provides an experienced commercial organization in the neuroscience market that we believe will be one of the highest growth areas for personalized medicine and completes our infrastructure expansion consistent with our four-in-six strategy."

"We are excited as a fellow pioneering company to be joining the global leader in personalized medicine," said Virginia C. Drosos, president and CEO, Assurex Health.  "As one of the world's leading molecular diagnostic companies, Myriad has the reimbursement, regulatory and commercial expertise to expand the long-term potential of Assurex's neuroscience products and ensure even more patients can benefit from better outcomes through our diagnostic tests."